What is Affinity Biosensors?
Affinity Biosensors specializes in rapid antimicrobial susceptibility testing (AST) through its innovative LifeScale system. This technology leverages advanced population profiling to deliver quick and accurate test results, a critical advantage for laboratories dealing with urgent patient care scenarios and the escalating challenge of antimicrobial resistance. The LifeScale system is designed for ease of use, integrating smoothly into existing laboratory workflows while providing reliable outputs in as little as 4 hours. The company targets healthcare institutions aiming to enhance patient outcomes via efficient microbiological testing.
How much funding has Affinity Biosensors raised?
Affinity Biosensors has raised a total of $15.2M across 6 funding rounds:
Private Equity
$1.3M
Series A
$7.1M
Private Equity
$4.8M
Debt
$150K
Debt
$347K
Private Equity
$1.6M
Private Equity (2013): $1.3M, investors not publicly disclosed
Series A (2016): $7.1M, investors not publicly disclosed
Private Equity (2017): $4.8M, investors not publicly disclosed
Debt (2020): $150K featuring PPP
Debt (2021): $347K backed by PPP
Private Equity (2026): $1.6M, investors not publicly disclosed
What's next for Affinity Biosensors?
The substantial enterprise-level funding and recent strategic investment position Affinity Biosensors for accelerated growth and market penetration. This financial backing is expected to fuel further development of their LifeScale system, enhance manufacturing capabilities, and expand their commercial reach into key global markets. The company's focus on rapid AST aligns with critical healthcare needs, suggesting a strategic trajectory towards becoming a leader in diagnostic solutions for infectious diseases and antimicrobial stewardship programs. Future endeavors will likely involve strengthening partnerships with healthcare providers and research institutions to validate and broaden the application of their technology.
See full Affinity Biosensors company page
